1. Home
  2. AR vs BMRN Comparison

AR vs BMRN Comparison

Compare AR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Antero Resources Corporation

AR

Antero Resources Corporation

HOLD

Current Price

$39.02

Market Cap

11.4B

Sector

Energy

ML Signal

HOLD

Logo BioMarin Pharmaceutical Inc.

BMRN

BioMarin Pharmaceutical Inc.

HOLD

Current Price

$49.88

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AR
BMRN
Founded
2002
1996
Country
United States
United States
Employees
632
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.4B
10.4B
IPO Year
2013
1999

Fundamental Metrics

Financial Performance
Metric
AR
BMRN
Price
$39.02
$49.88
Analyst Decision
Buy
Buy
Analyst Count
16
18
Target Price
$47.13
$88.22
AVG Volume (30 Days)
4.2M
1.7M
Earning Date
04-29-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
1027.78
N/A
EPS
1.72
0.54
Revenue
$5,275,823,000.00
$1,313,646,000.00
Revenue This Year
$29.74
$15.02
Revenue Next Year
$5.07
$12.23
P/E Ratio
$22.35
$91.80
Revenue Growth
21.97
17.62
52 Week Low
$29.10
$49.26
52 Week High
$45.75
$66.28

Technical Indicators

Market Signals
Indicator
AR
BMRN
Relative Strength Index (RSI) 56.24 32.95
Support Level $32.86 N/A
Resistance Level $40.08 $56.91
Average True Range (ATR) 1.08 1.82
MACD 0.20 -0.33
Stochastic Oscillator 81.77 7.34

Price Performance

Historical Comparison
AR
BMRN

About AR Antero Resources Corporation

Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Share on Social Networks: